Breaking News Instant updates and real-time market news.

SGEN

Seattle Genetics

$65.03

-2.55 (-3.77%)

, ALPMY

Astellas Pharma

$0.00

(0.00%)

07:33
06/03/19
06/03
07:33
06/03/19
07:33

Seattle Genetics, Astellas Pharma: Enfortumab vedotin rapidly shrank tumors

Astellas Pharma (ALPMY) and Seattle Genetics (SGEN) announced that data from the first cohort of a pivotal phase 2 clinical trial known as EV-201 demonstrated that the investigational agent enfortumab vedotin rapidly shrank tumors in most patients, resulting in an objective response rate of 44% (55/125). Complete responses were observed in 12% of patients (15/125). The median duration of tumor response was 7.6 months (range 0.95-11.3+). This cohort was open to patients with locally advanced or metastatic urothelial cancer who had received previous treatment with a platinum-containing chemotherapy and a PD-1/L1 checkpoint inhibitor. Responses were similar in the subgroups of patients analyzed, including those who had the worst prognosis, such as patients who had three or more previous lines of therapy, patients with liver metastases, and those who had not responded to a PD-1/L1 inhibitor. Treatment-related adverse events that occurred in 40% or more of patients were fatigue, alopecia, rash, decreased appetite, taste distortion, and peripheral neuropathy.

SGEN

Seattle Genetics

$65.03

-2.55 (-3.77%)

ALPMY

Astellas Pharma

$0.00

(0.00%)

  • 06

    Jun

SGEN Seattle Genetics
$65.03

-2.55 (-3.77%)

03/27/19
BREN
03/27/19
INITIATION
Target $95
BREN
Buy
Seattle Genetics initiated with a Buy at Berenberg
Berenberg analyst Shanshan Xu initiated Seattle Genetics with a Buy and $95 price target saying he sees further appreciation following strong performance over the past 12 months. Xu believes several assets are undervalued at current levels including tucatinib in Phase III development for breast cancer, and enfortumab in Phase III development for urothelial carcinoma. Further, the analyst believes the receipt of a Complete Response Letter for the Biologics License Application for lead product candidate IMMU-132 for breast cancer may be resolved following an inspection by the FDA in second half 2019.
03/28/19
PIPR
03/28/19
NO CHANGE
PIPR
Neutral
Seattle Genetics' ORR 'impressive' for third-line UBC, says Piper Jaffray
After Seattle Genetics (SGEN) reported topline results from the first cohort of patients in a phase 2 trial evaluating enfortumab vedotin for the treatment of patients with locally advanced or metastatic urothelial cancer who have received two prior lines of treatment, Piper Jaffray analyst Joseph Catanzaro said the 44% objective response rate, or ORR, was "impressive" in this population of patients. While he thinks there may be room for upward revisions to his assumptions, he prefers to wait for the full data set before making any changes. Catanzaro keeps a Neutral rating on Seattle Genetics, citing his concerns about the growth of Adcetris.
04/10/19
STFL
04/10/19
INITIATION
Target $70
STFL
Hold
Seattle Genetics initiated with a Hold at Stifel
Stifel analyst Stephen Willey initiated Seattle Genetics with a Hold rating and a price target of $70, saying that while the company "commands a leadership position in the development of antibody-drug conjugate technology", the current ADCETRIS estimates as "much-too-optimistic" in suggesting trajectory to sales of over $1B. The analyst adds that although the "recently-announced phase data for enfortumab vedotin will initiate Seattle Genetics' transition to a multi-product commercial company", he sees the "presumption of clinical/commercial success to be appropriately risk-adjusted in the stock at these levels."
04/25/19
PIPR
04/25/19
NO CHANGE
Target $64
PIPR
Neutral
Seattle Genetics Q1 marks third quarter of 'sluggish growth', says Piper Jaffray
Piper Jaffray analyst Joseph Catanzaro is keeping his Neutral rating and $64 price target on Seattle Genetics after its Q1 results that saw Adcetris sales of $135M missing consensus of $141M. The analyst notes that this marks the 3rd consecutive quarter of "sluggish growth", also lowering his FY19 EPS outlook to ($1.05) from (94c) and FY20 outlook to (14c) from 12c. Catanzaro lowers his FY19 Adcetris sales forecast to $611M from $633M, adding that the company's Adcentris revenue outlook of $610M-$640M for this year may "prove difficult."
ALPMY Astellas Pharma
$0.00

(0.00%)

06/08/18
GSCO
06/08/18
DOWNGRADE
GSCO
Neutral
Astellas Pharma downgraded to Neutral from Buy at Goldman Sachs
06/08/18
GSCO
06/08/18
DOWNGRADE
GSCO
Neutral
Goldman downgrades Astellas to Neutral with Xtandi growth priced in
Goldman Sachs analyst Akinori Ueda downgraded Astellas Pharma (ALPMY) to Neutral from Buy. Renewed appreciation for Xtandi's growth potential as well as Astellas' "proactive stance" on shareholder returns are largely priced into the stock, Ueda tells investors in a research note. With Japan Healthcare, the analyst prefers Santen Pharmaceutical, Shionogi and Sawai Pharmaceutical.
09/13/18
DBAB
09/13/18
DOWNGRADE
DBAB
Hold
Astellas Pharma downgraded to Hold from Buy at Deutsche Bank
Deutsche Bank analyst Joseph Cairnes downgraded Astellas Pharma to Hold with an unchanged price target of JPY 2,020. The analyst sees a more balanced risk/reward at current valuation levels.
11/05/18
JPMS
11/05/18
DOWNGRADE
JPMS
Underweight
Astellas Pharma downgraded to Underweight from Neutral at JPMorgan
JPMorgan analyst Naomi Kumagai downgraded Astellas Pharma to Underweight and lowered her price target for the shares to 1,400 yen from 1,600 yen. The analyst sees "many causes for concern."

TODAY'S FREE FLY STORIES

AXL

American Axle

$8.03

0.165 (2.10%)

10:25
10/15/19
10/15
10:25
10/15/19
10:25
Options
American Axle call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WNS

WNS Holdings

$59.25

-0.77 (-1.28%)

10:25
10/15/19
10/15
10:25
10/15/19
10:25
Conference/Events
WNS Holdings management to meet with Barrington »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

  • 22

    Oct

  • 11

    Nov

C

Citi

$70.26

-0.02 (-0.03%)

10:23
10/15/19
10/15
10:23
10/15/19
10:23
Hot Stocks
Breaking Hot Stocks news story on Citi »

Citi says accrual…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Oct

  • 15

    Oct

  • 12

    Nov

C

Citi

$70.29

0.01 (0.01%)

10:22
10/15/19
10/15
10:22
10/15/19
10:22
Hot Stocks
Breaking Hot Stocks news story on Citi »

Citi now sees net…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Oct

  • 15

    Oct

  • 12

    Nov

C

Citi

$70.29

0.01 (0.01%)

10:22
10/15/19
10/15
10:22
10/15/19
10:22
Hot Stocks
Citi sees expenses down sequentially in Q4, 'solid' pre-tax earnings growth »

For Q4 in ICG, Citi sees…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Oct

  • 15

    Oct

  • 12

    Nov

C

Citi

$70.27

-0.01 (-0.01%)

10:20
10/15/19
10/15
10:20
10/15/19
10:20
Hot Stocks
Breaking Hot Stocks news story on Citi »

Citi sttill sees…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Oct

  • 15

    Oct

  • 12

    Nov

IHRT

iHeartMedia

$14.51

-0.49 (-3.27%)

, SFIX

Stitch Fix

$21.01

-0.2 (-0.94%)

10:19
10/15/19
10/15
10:19
10/15/19
10:19
Initiation
Fly Intel: Top five analyst initiations »

Catch up on today's…

IHRT

iHeartMedia

$14.51

-0.49 (-3.27%)

SFIX

Stitch Fix

$21.01

-0.2 (-0.94%)

EHTH

eHealth

$55.75

2.63 (4.95%)

DS

Drive Shack

$4.01

0.28 (7.51%)

AMRN

Amarin

$15.56

0.12 (0.78%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 24

    Oct

  • 07

    Nov

  • 14

    Nov

  • 28

    Dec

BLMN

Bloomin' Brands

$17.27

-0.88 (-4.85%)

, ENB

Enbridge

$35.53

-0.08 (-0.22%)

10:19
10/15/19
10/15
10:19
10/15/19
10:19
Downgrade
Fly Intel: Top five analyst downgrades »

Catch up on today's…

BLMN

Bloomin' Brands

$17.27

-0.88 (-4.85%)

ENB

Enbridge

$35.53

-0.08 (-0.22%)

TGE

Tallgrass Energy

$19.35

-0.03 (-0.15%)

TEX

Terex

$24.98

-0.13 (-0.52%)

ATI

Allegheny Technologies

$20.15

-0.55 (-2.66%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Oct

  • 31

    Oct

  • 08

    Nov

BBBY

Bed Bath & Beyond

$12.26

-0.03 (-0.24%)

, LOW

Lowe's

$111.39

0.725 (0.66%)

10:19
10/15/19
10/15
10:19
10/15/19
10:19
Upgrade
Fly Intel: Top five analyst upgrades »

Catch up on today's…

BBBY

Bed Bath & Beyond

$12.26

-0.03 (-0.24%)

LOW

Lowe's

$111.39

0.725 (0.66%)

PINC

Premier

$31.20

0.78 (2.56%)

ZEAL

Zealand Pharma

$27.53

4.28 (18.41%)

IMO

Imperial Oil

$24.41

0.165 (0.68%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Nov

  • 19

    Nov

  • 20

    Nov

  • 20

    Nov

C

Citi

$70.17

-0.11 (-0.16%)

10:18
10/15/19
10/15
10:18
10/15/19
10:18
Hot Stocks
Breaking Hot Stocks news story on Citi »

Citi sees pre-tax loss of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Oct

  • 15

    Oct

  • 12

    Nov

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

10:17
10/15/19
10/15
10:17
10/15/19
10:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMBA

Ambarella

$54.38

1.27 (2.39%)

10:16
10/15/19
10/15
10:16
10/15/19
10:16
Recommendations
Ambarella analyst commentary  »

Ambarella ability to ship…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

$NYE

NYSE Market Internals

$0.00

(0.00%)

10:16
10/15/19
10/15
10:16
10/15/19
10:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ZM

Zoom Video

$70.27

-0.56 (-0.79%)

, PINS

Pinterest

$24.76

-1.215 (-4.68%)

10:11
10/15/19
10/15
10:11
10/15/19
10:11
Hot Stocks
Zoom Video, Pinterest slip as lock-ups for IPOs expire »

Shares of both Zoom Video…

ZM

Zoom Video

$70.27

-0.56 (-0.79%)

PINS

Pinterest

$24.76

-1.215 (-4.68%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Oct

  • 16

    Oct

  • 31

    Oct

  • 19

    Nov

  • 16

    Dec

C

Citi

$69.93

-0.35 (-0.50%)

10:11
10/15/19
10/15
10:11
10/15/19
10:11
Hot Stocks
Breaking Hot Stocks news story on Citi »

Citi CFO says to expand…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Oct

  • 15

    Oct

  • 12

    Nov

KNX

Knight-Swift

$35.47

-0.575 (-1.60%)

10:08
10/15/19
10/15
10:08
10/15/19
10:08
Recommendations
Knight-Swift analyst commentary  »

Knight-Swift guidance cut…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

C

Citi

$69.90

-0.38 (-0.54%)

10:07
10/15/19
10/15
10:07
10/15/19
10:07
Hot Stocks
Citi says environment is 'highly unpredictable,' waters 'choppy' »

CEO Mike Corbat says the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Oct

  • 15

    Oct

  • 12

    Nov

10:07
10/15/19
10/15
10:07
10/15/19
10:07
Conference/Events
JPMorgan agricultural/machinery analyst holds analyst/industry conference call »

Machinery Equity Analyst…

TLRY

Tilray

$22.00

1.35 (6.54%)

10:05
10/15/19
10/15
10:05
10/15/19
10:05
Options
Tilray call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

TNDM

TNDM

, ABT

Abbott

$81.63

1.82 (2.28%)

10:00
10/15/19
10/15
10:00
10/15/19
10:00
Recommendations
TNDM, Abbott, DexCom analyst commentary  »

Tandem, Abbott agreement…

TNDM

TNDM

ABT

Abbott

$81.63

1.82 (2.28%)

DXCM

DexCom

$147.49

-12.71 (-7.93%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

  • 04

    Nov

  • 06

    Nov

  • 13

    Nov

  • 14

    Nov

GM

General Motors

$35.28

-0.23 (-0.65%)

10:00
10/15/19
10/15
10:00
10/15/19
10:00
Periodicals
Breaking Periodicals news story on General Motors »

GM near agreement with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

UNH

UnitedHealth

$233.77

13.45 (6.10%)

10:00
10/15/19
10/15
10:00
10/15/19
10:00
Hot Stocks
UnitedHealth rises 5.9% »

UnitedHealth is up 5.9%,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Oct

DS

Drive Shack

$4.01

0.28 (7.51%)

10:00
10/15/19
10/15
10:00
10/15/19
10:00
Hot Stocks
Drive Shack rises 7.0% »

Drive Shack is up 7.0%,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

APHA

Aphria

$5.26

0.93 (21.48%)

10:00
10/15/19
10/15
10:00
10/15/19
10:00
Hot Stocks
Aphria rises 20.9% »

Aphria is up 20.9%, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Oct

  • 12

    Nov

WIT

Wipro

$3.76

0.07 (1.90%)

09:59
10/15/19
10/15
09:59
10/15/19
09:59
Earnings
Wipro sees Q3 IT Services business revenue $2.065B-$2.106B »

For the quarter ending…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Oct

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.